Benzatropine (previously known as benztropine) is an unlicensed medicine indicated for use as an alternative treatment of hypersalivation secondary to clozapine treatment in patients for whom adequate trials of hyoscine hydrobromide (both tablets and transdermal patches), trihexiphenidyl and pirenzepine have been ineffective either due to lack of efficacy or side effects.
It must not be used first line due to the unlicensed status.
Benzatropine was previously licensed for the management of extrapyramidal side effects (EPSE) secondary to antipsychotic treatment. This protocol does not cover the use of benzatropine for this indication due to other licensed preparations being available.